Sofinnova Investments

Seaport Therapeutics is a clinical stage biopharmaceutical company focused on developing innovative neuropsychiatric medicines for patients with significant unmet needs. The company's approach emphasizes the creation of treatments that offer oral bioavailability, which allows the medications to bypass first-pass metabolism. This method aims to reduce hepatotoxicity and other adverse side effects commonly associated with neuropsychiatric treatments. By addressing these critical issues, Seaport Therapeutics seeks to improve the quality of life for individuals living with neuropsychiatric disorders.

Aeovian Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapeutics for age-related and rare diseases. Founded in 2012 and based in the San Francisco Bay Area, the company specializes in compounds that inhibit the mTORC1 and mTORC2 pathways. These therapeutics aim to address the underlying causes of disease initiation and progression, including oxidative, cellular, and environmental stress. By targeting these fundamental factors, Aeovian Pharmaceuticals seeks to provide effective treatment options for patients and healthcare professionals.

Avenzo Therapeutics is a clinical-stage company focused on developing innovative oncology therapies aimed at treating cancer. The company’s platform is dedicated to creating novel treatments specifically for underserved cancers, including rare and genomically defined types. By advancing a pipeline of targeted drug candidates, Avenzo Therapeutics seeks to enhance treatment options for both researchers and patients, addressing significant gaps in current cancer care.

BioAge Labs, Inc. is a biotechnology company focused on developing therapies to address aging and age-related diseases. The company utilizes a systems biology and artificial intelligence platform to identify key drug targets that influence aging and analyze extensive datasets to uncover the molecular drivers of age-related conditions. BioAge Labs is advancing several drug candidates, including BGE-117, a hypoxia-inducible factor prolyl hydroxylase inhibitor designed to activate genes involved in critical biological processes such as tissue regeneration and vascular remodeling. Additionally, BGE-175, an orally administered inhibitor of the prostaglandin D2 DP1 signaling pathway, aims to mitigate risks associated with immune aging and respiratory infections. Founded in 2015 and based in Richmond, California, BioAge Labs is committed to discovering and developing innovative treatments that harness the biology of human aging.

OnCusp Therapeutics is a biopharmaceutical company turning cutting-edge research assets into innovative oncology treatments. It is always working to improve the largest value inflection point in the drug development value chain, believing that speeding oncology medication innovation is the most effective method to provide help and hope to cancer patients around the world. It is founded by Bing Yuan, Eric Slosberg, and Andy Fu.

Star Therapeutics is a biotechnology company focused on developing innovative therapies for a wide range of rare diseases. The company aims to identify diseases that share common biological characteristics and create novel therapeutics that can effectively treat multiple conditions with a single treatment. This approach not only addresses the needs of patients suffering from rare diseases but also presents a unique opportunity for pharmaceutical companies to broaden their therapeutic offerings within a streamlined pipeline. By concentrating on life-changing therapies, Star Therapeutics aspires to make a significant impact on the lives of millions of patients.

Rapport Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing innovative small-molecule therapies for neurological disorders. The company focuses on understanding the intricate biology of neuronal receptor complexes, which are essential for proper neuronal function and signaling. By mapping and targeting these receptor systems, Rapport Therapeutics aims to create precision medicines that can effectively address the unmet needs of patients suffering from central nervous system disorders. Through its foundational research, the company seeks to transform treatment options and improve outcomes for individuals with these challenging conditions.

Alkeus Pharmaceuticals is a Boston-based clinical-stage biopharmaceutical company dedicated to developing treatments for serious and untreatable ophthalmic conditions. The company's primary focus is on its lead drug candidate, an orally delivered compound aimed at addressing Stargardt disease and age-related macular degeneration. This innovative treatment has the potential to help medical professionals manage symptoms of irreversible vision loss early in life, offering hope to patients affected by these debilitating eye diseases.

Quanta Therapeutics is a biotechnology company focused on developing innovative cancer therapies targeting driver oncogenes, specifically RAS-driven cancers. The company employs advanced optical technology to discover small molecules that can modulate the conformation of RAS proteins. This allosteric modulation aims to restore conformational control of active RAS signaling at the cell membrane, thereby inhibiting a wide range of cancers associated with RAS mutations. By addressing the challenges of previously untreatable cancers, Quanta Therapeutics is committed to advancing new treatment options for patients and enhancing the understanding of RAS biology in cancer therapy.

Antiva Biosciences is a biopharmaceutical company based in South San Francisco, California, focused on developing antiviral drugs to treat human papillomavirus (HPV) infections. Founded in 2012 and previously known as Hera Therapeutics, the company aims to prevent cancer by addressing precancerous lesions associated with HPV. Antiva's innovative approach involves localized therapeutics and small molecule antivirals designed to improve health outcomes for patients suffering from diseases linked to HPV and other viruses. The company's clinical programs target high-grade anal intraepithelial neoplasias and high-grade cervical intraepithelial neoplasias, utilizing a medicinal chemistry platform that emphasizes the development and commercialization of direct-acting antivirals.

immatics is a biopharmaceutical company focused on the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The company's customized Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics are the two main product classes in the pipeline (TCER). With a focus on particularly difficult-to-treat solid malignancies, each therapy modality has unique characteristics to create the desired therapeutic impact for patients at various disease stages and with various types of tumors. immatics biotechnologies was established in 2000 by Hans Rammensee, Harpreet Singh, and Steffen Walter in Tübingen, Baden-Wurttemberg.

Antiva Biosciences is a biopharmaceutical company based in South San Francisco, California, focused on developing antiviral drugs to treat human papillomavirus (HPV) infections. Founded in 2012 and previously known as Hera Therapeutics, the company aims to prevent cancer by addressing precancerous lesions associated with HPV. Antiva's innovative approach involves localized therapeutics and small molecule antivirals designed to improve health outcomes for patients suffering from diseases linked to HPV and other viruses. The company's clinical programs target high-grade anal intraepithelial neoplasias and high-grade cervical intraepithelial neoplasias, utilizing a medicinal chemistry platform that emphasizes the development and commercialization of direct-acting antivirals.

Quanta Therapeutics is a biotechnology company focused on developing innovative cancer therapies targeting driver oncogenes, specifically RAS-driven cancers. The company employs advanced optical technology to discover small molecules that can modulate the conformation of RAS proteins. This allosteric modulation aims to restore conformational control of active RAS signaling at the cell membrane, thereby inhibiting a wide range of cancers associated with RAS mutations. By addressing the challenges of previously untreatable cancers, Quanta Therapeutics is committed to advancing new treatment options for patients and enhancing the understanding of RAS biology in cancer therapy.

CinCor Pharma, Inc. is a clinical-stage biopharmaceutical company based in Cincinnati, Ohio, established in 2018. The company is dedicated to developing clinical candidates targeting cardiovascular, metabolic, and kidney diseases. Its primary focus is on CIN-107, an aldosterone synthase inhibitor aimed at treating resistant hypertension and primary aldosteronism. CinCor Pharma's mission is to advance its promising clinical candidates toward marketing approval, emphasizing the development of innovative therapies for patients suffering from cardio-renal conditions.

XyloCor Therapeutics, based in Newtown Square, Pennsylvania, is a biopharmaceutical company dedicated to developing gene therapies for the treatment of cardiovascular diseases, particularly advanced coronary artery disease. Its lead product candidate, XC001, is currently in clinical development for patients suffering from refractory angina, addressing critical unmet medical needs for those who have exhausted conventional treatment options. Additionally, the company is developing XC002, aimed at regenerating cardiac tissue in patients with compromised heart function due to previous heart attacks and resultant heart failure. XyloCor's innovative gene therapy technologies focus on stimulating the formation of new coronary blood vessels, thereby improving blood supply to areas of the heart that are insufficiently perfused. The company collaborates with Weill Cornell Medical College to enhance its therapeutic approaches and outcomes for patients.

Vera Therapeutics, a biotechnology company based in South San Francisco, California, specializes in developing innovative biologic therapeutics aimed at treating serious immunological diseases and genetic disorders. Founded in 2016 and renamed in March 2020, the company's research focuses on transformative treatments that can significantly improve patient outcomes. One of its key product candidates is atacicept, a fusion protein designed for self-administration via a weekly subcutaneous injection. Atacicept works by inhibiting both B lymphocyte stimulator and a proliferation-inducing ligand, which are involved in the production of autoantibodies that contribute to various autoimmune diseases. Additionally, Vera Therapeutics is exploring gene-editing technologies that hold the potential to address conditions such as sickle cell disease and cystic fibrosis.

VelosBio, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative antibody-drug conjugates (ADCs) to treat various forms of cancer, including hematological cancers and solid tumors. The company's primary area of research centers on targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1), a cell-surface protein found in numerous tumors but absent in normal tissues, which makes it a promising target for cancer therapy. VelosBio's lead product, VLS-101, is a ROR1-directed ADC that has shown positive preclinical results and aims to provide new treatment options for patients. Founded in 2017, VelosBio operates under the umbrella of Merck & Co., Inc. as of December 2020, focusing on developing targeted therapies that can be administered alone or in combination with other treatments across a wide range of cancer types.

Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing novel immunotherapies for cancer treatment. The company specializes in CpG oligonucleotides, which are designed to stimulate an anti-tumor T-cell response while counteracting the mechanisms that tumors use to evade the immune response. Checkmate aims to enhance the effectiveness of existing immunotherapies and provide new treatment options for patients through its innovative approaches. Since its incorporation in 2015, Checkmate has established strategic partnerships with major pharmaceutical companies, including Merck KGaA and Pfizer, to advance its clinical programs and broaden the impact of its research in the field of cancer immunotherapy.

Athira Pharma, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, focused on developing small molecules aimed at restoring neuronal health and addressing neurodegenerative diseases. The company's lead candidate, ATH-1017, is a small hepatocyte growth factor/MET activator designed to penetrate the blood-brain barrier and is currently undergoing various clinical trials for the treatment of Alzheimer's and Parkinson's diseases. Additionally, Athira is advancing other candidates, including ATH-1019, which is in preclinical development for depression, and ATH-1018, aimed at treating peripheral neuropathy. Founded in 2011 and originally named M3 Biotechnology, Athira Pharma changed its name in April 2019 to reflect its commitment to innovative therapies that positively impact individuals affected by brain disorders.

Amplyx Pharmaceuticals is a pre-clinical stage company focusing on the development of small molecule drugs with enhanced efficacy and lower toxicity. Amplyx employs a platform approach to improve small molecule drugs by the addition of a second small molecule to an existing drug. The company develops innovative therapies for debilitating and life-threatening diseases that affect people with compromised immune systems. Amplyx Pharmaceuticals was founded in 2006 and is headquartered in San Diego, California.

NorthSea Therapeutics B.V. is a biotechnology company focused on developing and manufacturing innovative therapeutics for metabolic, inflammatory, and fibrotic diseases. Established in 2017 and based in Naarden, the Netherlands, the company utilizes its proprietary Structurally Engineered Fatty Acid (SEFA) technology to create unique oral therapeutic candidates. One of its leading products, icosabutate, is designed to address inflammatory and liver diseases by offering a novel approach to treatment. The company's pipeline includes candidates that aim to improve conditions such as dyslipidemia, insulin resistance, hepatic inflammation, and fibrosis, providing healthcare providers with effective options for patient care.

Vera Therapeutics, a biotechnology company based in South San Francisco, California, specializes in developing innovative biologic therapeutics aimed at treating serious immunological diseases and genetic disorders. Founded in 2016 and renamed in March 2020, the company's research focuses on transformative treatments that can significantly improve patient outcomes. One of its key product candidates is atacicept, a fusion protein designed for self-administration via a weekly subcutaneous injection. Atacicept works by inhibiting both B lymphocyte stimulator and a proliferation-inducing ligand, which are involved in the production of autoantibodies that contribute to various autoimmune diseases. Additionally, Vera Therapeutics is exploring gene-editing technologies that hold the potential to address conditions such as sickle cell disease and cystic fibrosis.

Intrepida Bio, Inc. is a biotechnology company focused on developing innovative cancer therapies by targeting the body's innate immune system. Incorporated in 2016 and based in San Diego, California, the company aims to create medicines that modulate innate immunity to combat cancer and other diseases. Utilizing proprietary monoclonal antibodies, Intrepida Bio works on blocking novel targets, specifically BAG3 and its receptor IFITM-2, to disrupt the tumor-supportive environment. Through this approach, the company seeks to provide patients with effective treatment options that may improve outcomes in cancer care.

Aeovian Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapeutics for age-related and rare diseases. Founded in 2012 and based in the San Francisco Bay Area, the company specializes in compounds that inhibit the mTORC1 and mTORC2 pathways. These therapeutics aim to address the underlying causes of disease initiation and progression, including oxidative, cellular, and environmental stress. By targeting these fundamental factors, Aeovian Pharmaceuticals seeks to provide effective treatment options for patients and healthcare professionals.

CinCor Pharma, Inc. is a clinical-stage biopharmaceutical company based in Cincinnati, Ohio, established in 2018. The company is dedicated to developing clinical candidates targeting cardiovascular, metabolic, and kidney diseases. Its primary focus is on CIN-107, an aldosterone synthase inhibitor aimed at treating resistant hypertension and primary aldosteronism. CinCor Pharma's mission is to advance its promising clinical candidates toward marketing approval, emphasizing the development of innovative therapies for patients suffering from cardio-renal conditions.

Karuna Therapeutics is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, dedicated to developing innovative therapies for neuropsychiatric disorders and pain. Its lead product candidate, KarXT, is an oral modulator that has completed a Phase II clinical trial for treating acute psychosis in schizophrenia patients and is undergoing a Phase Ib clinical trial for various central nervous system disorders, including cognitive and negative symptoms of schizophrenia, Alzheimer’s, and dementia-related psychosis. The company is also developing additional muscarinic-targeted drug candidates to address unmet medical needs in these areas. Founded in 2009, Karuna Therapeutics has established partnerships with organizations such as Eli Lilly and Company and PureTech Health LLC, focusing on advancing its drug discovery efforts through collaborations with Charles River Laboratories and PsychoGenics Inc.

Promedior, Inc. is a clinical-stage biotechnology company based in Lexington, Massachusetts, focused on developing therapeutics for rare fibrotic and inflammatory diseases. The company’s primary targets include conditions such as myelofibrosis, idiopathic pulmonary fibrosis, age-related macular degeneration, and diabetic retinopathy. Promedior's drug portfolio features PRM-151, a recombinant form of human pentaxin-2 protein, and PRM-167, a variant designed for intravitreal delivery. These therapeutics are aimed at regulating monocyte-derived cell populations, which are critical in fibrotic, inflammatory, and autoimmune diseases. By specifically addressing these cells at injury sites, Promedior seeks to promote tissue healing and minimize systemic side effects commonly associated with existing therapies. The company was incorporated in 2006 and was previously known as Fibrotix, Inc.

NorthSea Therapeutics B.V. is a biotechnology company focused on developing and manufacturing innovative therapeutics for metabolic, inflammatory, and fibrotic diseases. Established in 2017 and based in Naarden, the Netherlands, the company utilizes its proprietary Structurally Engineered Fatty Acid (SEFA) technology to create unique oral therapeutic candidates. One of its leading products, icosabutate, is designed to address inflammatory and liver diseases by offering a novel approach to treatment. The company's pipeline includes candidates that aim to improve conditions such as dyslipidemia, insulin resistance, hepatic inflammation, and fibrosis, providing healthcare providers with effective options for patient care.

XyloCor Therapeutics, based in Newtown Square, Pennsylvania, is a biopharmaceutical company dedicated to developing gene therapies for the treatment of cardiovascular diseases, particularly advanced coronary artery disease. Its lead product candidate, XC001, is currently in clinical development for patients suffering from refractory angina, addressing critical unmet medical needs for those who have exhausted conventional treatment options. Additionally, the company is developing XC002, aimed at regenerating cardiac tissue in patients with compromised heart function due to previous heart attacks and resultant heart failure. XyloCor's innovative gene therapy technologies focus on stimulating the formation of new coronary blood vessels, thereby improving blood supply to areas of the heart that are insufficiently perfused. The company collaborates with Weill Cornell Medical College to enhance its therapeutic approaches and outcomes for patients.

Visen Pharmaceuticals is a biopharmaceutical company that specializes in the development and commercialization of innovative therapies for endocrine diseases. The company is dedicated to addressing significant unmet medical needs in this field, particularly within the Chinese market, and aims to provide both first-in-class and best-in-class treatment solutions for patients of all ages, including those with rare endocrine conditions. With a commitment to patient-centric care, Visen strives to improve treatment outcomes and quality of life for individuals affected by these diseases. The company is backed by a team of experienced professionals with extensive backgrounds in the pharmaceutical industry and operates offices in major Chinese cities such as Shanghai, Beijing, Hong Kong, and Taipei. To further enhance its research, development, and manufacturing capabilities, Visen has established a Greater China research and development site in Suzhou, aiming to deliver advanced treatment options to Chinese patients more effectively.

NextCure, Inc. is a clinical-stage biopharmaceutical company based in Beltsville, Maryland, that specializes in the discovery and development of novel immunomedicines aimed at treating cancer and other immune-related diseases. The company focuses on restoring normal immune function through its lead product candidate, NC318, currently in Phase 2 clinical trials for advanced or metastatic solid tumors. In addition, NextCure is developing NC410, an immunomedicine designed to inhibit immune suppression mediated by Leukocyte-Associated Immunoglobulin-like Receptor 1. The company's research also includes preclinical programs targeting various immunomodulatory proteins associated with tumors and inflamed tissues. NextCure has established collaborations, including a licensing agreement with Yale University and a research partnership with Eli Lilly and Company, to further its innovative therapeutic approaches. Founded in 2015, NextCure is dedicated to advancing first-in-class immunotherapy solutions.

VelosBio, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative antibody-drug conjugates (ADCs) to treat various forms of cancer, including hematological cancers and solid tumors. The company's primary area of research centers on targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1), a cell-surface protein found in numerous tumors but absent in normal tissues, which makes it a promising target for cancer therapy. VelosBio's lead product, VLS-101, is a ROR1-directed ADC that has shown positive preclinical results and aims to provide new treatment options for patients. Founded in 2017, VelosBio operates under the umbrella of Merck & Co., Inc. as of December 2020, focusing on developing targeted therapies that can be administered alone or in combination with other treatments across a wide range of cancer types.

Antiva Biosciences is a biopharmaceutical company based in South San Francisco, California, focused on developing antiviral drugs to treat human papillomavirus (HPV) infections. Founded in 2012 and previously known as Hera Therapeutics, the company aims to prevent cancer by addressing precancerous lesions associated with HPV. Antiva's innovative approach involves localized therapeutics and small molecule antivirals designed to improve health outcomes for patients suffering from diseases linked to HPV and other viruses. The company's clinical programs target high-grade anal intraepithelial neoplasias and high-grade cervical intraepithelial neoplasias, utilizing a medicinal chemistry platform that emphasizes the development and commercialization of direct-acting antivirals.

ENYO Pharma SA is a clinical-stage biopharmaceutical company based in Lyon, France, that focuses on the discovery and development of innovative treatments for acute and chronic viral infections. Established in 2014 by a team of scientists from the Infectiology Research Center, the company utilizes a proprietary platform to identify intracellular therapeutic targets and develop small molecule therapeutics. ENYO Pharma's research primarily targets significant human infecting viruses, with current programs aimed at treating chronic hepatitis B and severe influenza. The company's pipeline includes a lead compound, EYP001, which modulates FXR to reduce the cccDNA reservoir and inhibit the expression of viral proteins, along with EYP002, which is in preclinical studies. With an emphasis on addressing unmet medical needs in infectious diseases and metabolic disorders, ENYO Pharma has established collaborations with prominent research institutions to enhance its drug development efforts.

Neurana Pharmaceuticals is a biotechnology company that is currently developing a novel treatment for acute muscle spasms. The company was founded in 2013 and headquartered in California, United States.

Merus B.V. is a clinical-stage biomedical company focused on the discovery and development of antibody-based biopharmaceuticals, specifically in the field of immuno-oncology. The company utilizes its proprietary Oligoclonics technology to produce a class of human antibodies, which allows for the creation of a mixture of therapeutic antibodies targeting a common antigen from a single cell clone. Additionally, Merus develops bispecific antibody therapeutics known as Biclonics, which are designed to engage multiple targets simultaneously. The company's pipeline includes several product candidates such as MCLA-128, MCLA-117, and MCLA-158, among others, all aimed at addressing various cancer indications.

Kiniksa Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing therapeutic medicines for patients with debilitating diseases and significant unmet medical needs. The company has a diverse pipeline of product candidates, primarily targeting autoinflammatory and autoimmune conditions. Its clinical-stage candidates include Rilonacept, currently in Phase III trials for recurrent pericarditis; Mavrilimumab, a monoclonal antibody in Phase II trials for giant cell arteritis; and KPL-716, which is undergoing Phase 2a trials for prurigo nodularis and Phase 1a trials for atopic dermatitis. Additionally, Kiniksa is developing KPL-404, a preclinical monoclonal antibody aimed at modulating T-cell-dependent and B-cell-mediated immunity. The company also has a collaboration with Kite Pharma to explore the combination of Mavrilimumab and Yescarta for patients with relapsed or refractory Large B-Cell lymphoma. Founded in 2015 and based in Hamilton, Bermuda, Kiniksa Pharmaceuticals employs a disciplined approach to identify and advance product candidates with strong biological rationales.

Quanta Therapeutics is a biotechnology company focused on developing innovative cancer therapies targeting driver oncogenes, specifically RAS-driven cancers. The company employs advanced optical technology to discover small molecules that can modulate the conformation of RAS proteins. This allosteric modulation aims to restore conformational control of active RAS signaling at the cell membrane, thereby inhibiting a wide range of cancers associated with RAS mutations. By addressing the challenges of previously untreatable cancers, Quanta Therapeutics is committed to advancing new treatment options for patients and enhancing the understanding of RAS biology in cancer therapy.

YmAbs is a clinical stage biopharmaceutical company that discovers and develops innovative treatments for cancer patients through immunotherapies. YmAbs utilizes its platform technologies to create next-generation humanized, affinity matured bispecific antibodies. To further improve its bispecific antibodies, the company collaborates on the development of a novel human protein tag that dimerizes T-cell engaging bispecific antibodies, which enables higher tumor binding and results in a longer serum half-life and a significantly greater T-cell mediated killing of tumor cells. YmAbs' treatments claims to potentially reduce longer-term toxicities associated with current chemotherapeutics and provide the potential for curative therapy even for patients with widespread disease. YmAbs’ goal is to drive multiple product candidates in select solid tumor cancers to FDA approval.

Medeor Therapeutics, Inc. is a biotechnology company based in San Mateo, California, focused on researching, developing, and commercializing personalized cellular immunotherapies. Founded in 2012, the company specializes in creating innovative treatments aimed at improving outcomes for kidney transplant recipients. Under the MDR-10X brand, Medeor Therapeutics develops cellular immunotherapy products that enhance organ transplant immune tolerance and advance immuno-oncology. These therapies are designed to better preserve or improve kidney function and reduce the risk of graft rejection compared to traditional immunosuppressive drugs.

Entasis Therapeutics is a late-stage clinical biopharmaceutical company dedicated to developing innovative treatments for serious infections caused by multidrug-resistant Gram-negative bacteria, a growing global health concern. The company’s anti-infective discovery platform has led to a diverse pipeline of differentiated drug candidates, including ETX2514SUL and SUL-DUR, which target Acinetobacter baumannii, zoliflodacin for Neisseria gonorrhoeae, and ETX0282CPDP aimed at Enterobacterales. Additionally, ETX0462 is being developed to address infections caused by Pseudomonas. Through its focused efforts, Entasis Therapeutics aims to provide effective solutions for patients suffering from these challenging bacterial infections.

Apellis Pharmaceuticals is an early-stage biotechnology company focused on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease. The company is leveraging courageous science, creativity, and compassion to deliver life-changing medicines. They aim to develop best-in-class and first-in-class therapies for a broad range of debilitating diseases that are driven by uncontrolled or excessive activation of the complement cascade, including those within hematology, ophthalmology, nephrology, and neurology. It was founded in 2008 and headquartered in Waltham, Massachusetts, United States.

Amplyx Pharmaceuticals is a pre-clinical stage company focusing on the development of small molecule drugs with enhanced efficacy and lower toxicity. Amplyx employs a platform approach to improve small molecule drugs by the addition of a second small molecule to an existing drug. The company develops innovative therapies for debilitating and life-threatening diseases that affect people with compromised immune systems. Amplyx Pharmaceuticals was founded in 2006 and is headquartered in San Diego, California.

Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing novel immunotherapies for cancer treatment. The company specializes in CpG oligonucleotides, which are designed to stimulate an anti-tumor T-cell response while counteracting the mechanisms that tumors use to evade the immune response. Checkmate aims to enhance the effectiveness of existing immunotherapies and provide new treatment options for patients through its innovative approaches. Since its incorporation in 2015, Checkmate has established strategic partnerships with major pharmaceutical companies, including Merck KGaA and Pfizer, to advance its clinical programs and broaden the impact of its research in the field of cancer immunotherapy.

Antiva Biosciences is a biopharmaceutical company based in South San Francisco, California, focused on developing antiviral drugs to treat human papillomavirus (HPV) infections. Founded in 2012 and previously known as Hera Therapeutics, the company aims to prevent cancer by addressing precancerous lesions associated with HPV. Antiva's innovative approach involves localized therapeutics and small molecule antivirals designed to improve health outcomes for patients suffering from diseases linked to HPV and other viruses. The company's clinical programs target high-grade anal intraepithelial neoplasias and high-grade cervical intraepithelial neoplasias, utilizing a medicinal chemistry platform that emphasizes the development and commercialization of direct-acting antivirals.

Dauntless Pharmaceuticals is a therapeutics company that focuses on the development of drugs. The traditional biotech company holds numerous assets at various stages of development, and its investors, management, labs, and staff collectively share an interest in all company assets. It was founded in 2015 and headquartered in San Diego, California.

Ascendis Pharma A/S is a biopharmaceutical company based in Hellerup, Denmark, focused on developing prodrug therapies to address unmet medical needs. Leveraging its innovative TransCon technology platform, the company aims to create superior prodrugs across various drug classes, including proteins, peptides, and small molecules. Its pipeline includes TransCon growth hormone, which has completed Phase III clinical trials for treating growth hormone deficiency in children, and TransCon parathyroid hormone, currently in Phase II trials for hypoparathyroidism. Additionally, TransCon CNP is in Phase II development for achondroplasia. Ascendis Pharma also explores preclinical studies in oncology and employs strategic collaborations to enhance its product development, aiming for systemic and localized drug delivery. The company primarily operates in North America, with additional activities in Europe and China.

NextCure, Inc. is a clinical-stage biopharmaceutical company based in Beltsville, Maryland, that specializes in the discovery and development of novel immunomedicines aimed at treating cancer and other immune-related diseases. The company focuses on restoring normal immune function through its lead product candidate, NC318, currently in Phase 2 clinical trials for advanced or metastatic solid tumors. In addition, NextCure is developing NC410, an immunomedicine designed to inhibit immune suppression mediated by Leukocyte-Associated Immunoglobulin-like Receptor 1. The company's research also includes preclinical programs targeting various immunomodulatory proteins associated with tumors and inflamed tissues. NextCure has established collaborations, including a licensing agreement with Yale University and a research partnership with Eli Lilly and Company, to further its innovative therapeutic approaches. Founded in 2015, NextCure is dedicated to advancing first-in-class immunotherapy solutions.

Dauntless Pharmaceuticals is a therapeutics company that focuses on the development of drugs. The traditional biotech company holds numerous assets at various stages of development, and its investors, management, labs, and staff collectively share an interest in all company assets. It was founded in 2015 and headquartered in San Diego, California.

Aclaris Therapeutics started by the founders of Vicept Therapeutics, is a privately held specialty pharmaceutical dermatology company focused on the development of novel dermatologic therapies. It is committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in dermatology, both medical and aesthetic, and immunology. Aclaris is focused on market segments with no FDA-approved medications or where treatment gaps exist.

Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing novel immunotherapies for cancer treatment. The company specializes in CpG oligonucleotides, which are designed to stimulate an anti-tumor T-cell response while counteracting the mechanisms that tumors use to evade the immune response. Checkmate aims to enhance the effectiveness of existing immunotherapies and provide new treatment options for patients through its innovative approaches. Since its incorporation in 2015, Checkmate has established strategic partnerships with major pharmaceutical companies, including Merck KGaA and Pfizer, to advance its clinical programs and broaden the impact of its research in the field of cancer immunotherapy.

Principia Biopharma is a private, pre-clinical stage company initially focused on the discovery and development of differentiated small molecule drugs targeting inflammatory/autoimmune diseases as well as cancer. The company expects to submit an IND for its lead program in 2013 and continues to invest in additional programs and its reversible covalent platform.

Antiva Biosciences is a biopharmaceutical company based in South San Francisco, California, focused on developing antiviral drugs to treat human papillomavirus (HPV) infections. Founded in 2012 and previously known as Hera Therapeutics, the company aims to prevent cancer by addressing precancerous lesions associated with HPV. Antiva's innovative approach involves localized therapeutics and small molecule antivirals designed to improve health outcomes for patients suffering from diseases linked to HPV and other viruses. The company's clinical programs target high-grade anal intraepithelial neoplasias and high-grade cervical intraepithelial neoplasias, utilizing a medicinal chemistry platform that emphasizes the development and commercialization of direct-acting antivirals.

Dauntless Pharmaceuticals is a therapeutics company that focuses on the development of drugs. The traditional biotech company holds numerous assets at various stages of development, and its investors, management, labs, and staff collectively share an interest in all company assets. It was founded in 2015 and headquartered in San Diego, California.

Mirna Therapeutics, Inc. (Mirna) is a discovery-stage biopharmaceutical research and development company focused on miRNA-directed human oncology therapies. Featuring world-class research capabilities, a strong understanding of miRNA and cancer biology, and an expansive IP portfolio, Mirna Therapeutics is well-positioned to capitalize on the emerging field of miRNA-based therapeutics.

Merus B.V. is a clinical-stage biomedical company focused on the discovery and development of antibody-based biopharmaceuticals, specifically in the field of immuno-oncology. The company utilizes its proprietary Oligoclonics technology to produce a class of human antibodies, which allows for the creation of a mixture of therapeutic antibodies targeting a common antigen from a single cell clone. Additionally, Merus develops bispecific antibody therapeutics known as Biclonics, which are designed to engage multiple targets simultaneously. The company's pipeline includes several product candidates such as MCLA-128, MCLA-117, and MCLA-158, among others, all aimed at addressing various cancer indications.

Natera, Inc. is a diagnostic company that specializes in preconception and prenatal genetic testing services. Its primary offerings include the Panorama test, which is a non-invasive prenatal test that screens for chromosomal abnormalities in a fetus through a blood sample from the mother, and the Vistara test, designed to identify single-gene disorders. Additionally, Natera provides Horizon carrier screening to determine genetic disease carrier status and Spectrum, which analyzes chromosomal anomalies during in vitro fertilization. The company also offers Anora, a test for analyzing fetal chromosomes to investigate miscarriage causes, and non-invasive paternity testing. Its Signatera product utilizes circulating tumor DNA technology to monitor cancer recurrence. Natera markets its tests through a direct sales force and a network of approximately 100 laboratory and distribution partners both domestically and internationally. The company, founded in 2003 and headquartered in San Carlos, California, maintains partnerships with BGI Genomics and Foundation Medicine for the development of genetic testing assays.

Chiasma, Inc. is a late-stage biopharmaceutical company based in Needham, Massachusetts, that specializes in developing oral medications for rare and serious chronic diseases. Utilizing its proprietary Transient Permeability Enhancer technology, Chiasma aims to transform injectable drugs into oral formulations, enhancing their absorption and potentially enabling new therapeutic indications. The company is currently focused on MYCAPSSA, an oral octreotide capsule designed for adult patients with acromegaly, a condition characterized by excessive growth hormone production. MYCAPSSA is undergoing Phase III clinical trials in the United States and is also in the process of seeking regulatory approval in the European Union. Founded in 2001, Chiasma is dedicated to improving treatment options for patients with debilitating conditions through innovative drug delivery methods.

NextCure, Inc. is a clinical-stage biopharmaceutical company based in Beltsville, Maryland, that specializes in the discovery and development of novel immunomedicines aimed at treating cancer and other immune-related diseases. The company focuses on restoring normal immune function through its lead product candidate, NC318, currently in Phase 2 clinical trials for advanced or metastatic solid tumors. In addition, NextCure is developing NC410, an immunomedicine designed to inhibit immune suppression mediated by Leukocyte-Associated Immunoglobulin-like Receptor 1. The company's research also includes preclinical programs targeting various immunomodulatory proteins associated with tumors and inflamed tissues. NextCure has established collaborations, including a licensing agreement with Yale University and a research partnership with Eli Lilly and Company, to further its innovative therapeutic approaches. Founded in 2015, NextCure is dedicated to advancing first-in-class immunotherapy solutions.

Ascendis Pharma A/S is a biopharmaceutical company based in Hellerup, Denmark, focused on developing prodrug therapies to address unmet medical needs. Leveraging its innovative TransCon technology platform, the company aims to create superior prodrugs across various drug classes, including proteins, peptides, and small molecules. Its pipeline includes TransCon growth hormone, which has completed Phase III clinical trials for treating growth hormone deficiency in children, and TransCon parathyroid hormone, currently in Phase II trials for hypoparathyroidism. Additionally, TransCon CNP is in Phase II development for achondroplasia. Ascendis Pharma also explores preclinical studies in oncology and employs strategic collaborations to enhance its product development, aiming for systemic and localized drug delivery. The company primarily operates in North America, with additional activities in Europe and China.

Invitae is a genetic information company focused on integrating genetic insights into everyday medical practice to enhance healthcare quality for a large population. The company specializes in genetic diagnostics for hereditary disorders, offering a comprehensive service that consolidates multiple genetic tests into a single platform. Invitae's offerings include assessments for genes linked to hereditary cancer, neurological disorders, cardiovascular conditions, pediatric issues, metabolic disorders, and other hereditary ailments. By providing high-quality testing with quicker turnaround times and competitive pricing, Invitae aims to make genetic testing more accessible and effective for patients and healthcare providers alike.

Aclaris Therapeutics started by the founders of Vicept Therapeutics, is a privately held specialty pharmaceutical dermatology company focused on the development of novel dermatologic therapies. It is committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in dermatology, both medical and aesthetic, and immunology. Aclaris is focused on market segments with no FDA-approved medications or where treatment gaps exist.

Civitas Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative pulmonary delivery therapies. Utilizing its proprietary ARCUS technology, the company creates therapeutics aimed at treating central nervous system and respiratory disorders. Civitas Therapeutics serves patients across the United States, focusing on delivering transformative treatment options to improve health outcomes.

Spark Therapeutics, Inc. is a biotechnology company focused on developing gene therapy products aimed at treating debilitating genetic diseases. Headquartered in Philadelphia, Pennsylvania, the company was founded in 2013 and has established itself as a leader in the field of gene therapy, with a robust pipeline that includes LUXTURNA for retinal dystrophy, as well as several candidates for hemophilia and choroideremia. Spark is also exploring therapies for neurodegenerative diseases and inherited retinal diseases. The company holds a collaboration agreement with Pfizer for the development of hemophilia B treatments and has partnered with Novartis for the commercialization of its lead product outside the United States. Spark Therapeutics leverages a proprietary manufacturing platform and a team with extensive expertise in research, clinical development, and regulatory affairs, building on a legacy of innovation in gene therapy from its origins at The Children’s Hospital of Philadelphia. As of December 2019, Spark operates as a subsidiary of Roche Holding AG.

Coherus Biosciences is a biopharmaceutical company that specializes in the development, manufacture, and commercialization of biologic therapeutics, with a primary focus on oncology and inflammatory diseases. The company has established a portfolio of FDA-approved products, including UDENYCA, a biosimilar to Neulasta, and is preparing to launch YUSIMRY, a biosimilar to Humira, in the United States in 2023. Coherus's development efforts emphasize process science, analytical characterization, and clinical-regulatory development. The company's pipeline includes candidates for Immunology, ophthalmology, and oncology, particularly targeting anti-tumor necrosis factor therapies. By leveraging its diverse portfolio, Coherus aims to build a robust immuno-oncology franchise while generating revenue primarily from the U.S. market.

Principia Biopharma is a private, pre-clinical stage company initially focused on the discovery and development of differentiated small molecule drugs targeting inflammatory/autoimmune diseases as well as cancer. The company expects to submit an IND for its lead program in 2013 and continues to invest in additional programs and its reversible covalent platform.

NuCana is a clinical-stage biopharmaceutical company dedicated to improving treatment outcomes for cancer patients through its proprietary ProTide technology. This innovative approach aims to transform commonly prescribed chemotherapy agents into safer and more effective medicines by overcoming key mechanisms of cancer resistance and enhancing the concentration of anti-cancer metabolites within tumor cells. The company is developing a portfolio of first-in-class and best-in-class pharmaceutical products, including NUC-3373, NUC-7738, and Acelarin, primarily focusing on oncology, while also maintaining the potential for broader clinical applications. With a management team experienced in the biopharmaceutical industry, NuCana is committed to addressing significant unmet medical needs in cancer treatment.

NuCana is a clinical-stage biopharmaceutical company dedicated to improving treatment outcomes for cancer patients through its proprietary ProTide technology. This innovative approach aims to transform commonly prescribed chemotherapy agents into safer and more effective medicines by overcoming key mechanisms of cancer resistance and enhancing the concentration of anti-cancer metabolites within tumor cells. The company is developing a portfolio of first-in-class and best-in-class pharmaceutical products, including NUC-3373, NUC-7738, and Acelarin, primarily focusing on oncology, while also maintaining the potential for broader clinical applications. With a management team experienced in the biopharmaceutical industry, NuCana is committed to addressing significant unmet medical needs in cancer treatment.

ZS Pharma is a privately held specialty pharmaceutical company based in Coppell, Texas, and Menlo Park, CA. Its core focus is the research and development of highly selective ion-trap therapies to treat serious medical conditions. The company'ss therapeutic candidate, ZS-9, is a novel treatment for hyperkalemia, a life-threatening condition that affects patients with chronic kidney disease, hypertension, diabetes, and/or chronic heart failure. Hyperkalemia is characterized by abnormally high concentrations of potassium in the blood. ZS-9 is currently being tested in late-stage clinical trials.

Natera, Inc. is a diagnostic company that specializes in preconception and prenatal genetic testing services. Its primary offerings include the Panorama test, which is a non-invasive prenatal test that screens for chromosomal abnormalities in a fetus through a blood sample from the mother, and the Vistara test, designed to identify single-gene disorders. Additionally, Natera provides Horizon carrier screening to determine genetic disease carrier status and Spectrum, which analyzes chromosomal anomalies during in vitro fertilization. The company also offers Anora, a test for analyzing fetal chromosomes to investigate miscarriage causes, and non-invasive paternity testing. Its Signatera product utilizes circulating tumor DNA technology to monitor cancer recurrence. Natera markets its tests through a direct sales force and a network of approximately 100 laboratory and distribution partners both domestically and internationally. The company, founded in 2003 and headquartered in San Carlos, California, maintains partnerships with BGI Genomics and Foundation Medicine for the development of genetic testing assays.

Innocoll is a privately held biopharmaceutical company specializing in collagen-based pharmaceutical products and medical devices. The company develops biodegradable surgical implants and topically applied healthcare solutions aimed at enhancing patient care in various medical contexts. Its product lineup includes CollaGUARD, a bioresorbable collagen film to prevent post-operative adhesions, and Collatamp Gentamicin, which helps treat or prevent surgical infections. Septocoll serves as a dual-action sponge for infection management, while RegenePro is designed for dental applications. Innocoll is also advancing product candidates like XaraColl, currently in phase III trials for post-operative pain relief, and Cogenzia, aimed at diabetic foot infections. With its headquarters in Athlone, Ireland, Innocoll utilizes a proprietary technology platform to create products that are fully bioresorbable, offering non-opioid alternatives for pain management in surgical settings.

Ziarco, Inc. is a biotechnology company founded in 2012 and based in Palo Alto, California. The company specializes in the development of therapeutic agents aimed at treating inflammatory and allergic diseases. Its primary focus is on inflammatory skin disorders, and its product pipeline includes a histamine H4 receptor antagonist program targeting various conditions such as asthma, allergic rhinitis, pruritus, skin diseases, and pain. Ziarco's innovations aim to provide effective treatment options for patients suffering from atopic dermatitis and psoriasis, enhancing their quality of life through improved therapeutic solutions.

Invitae is a genetic information company focused on integrating genetic insights into everyday medical practice to enhance healthcare quality for a large population. The company specializes in genetic diagnostics for hereditary disorders, offering a comprehensive service that consolidates multiple genetic tests into a single platform. Invitae's offerings include assessments for genes linked to hereditary cancer, neurological disorders, cardiovascular conditions, pediatric issues, metabolic disorders, and other hereditary ailments. By providing high-quality testing with quicker turnaround times and competitive pricing, Invitae aims to make genetic testing more accessible and effective for patients and healthcare providers alike.

ObsEva SA is a Swiss-based, speciality biopharmaceutical company dedicated to the development of innovative drugs for women's reproductive medicine. ObsEva's main focus is on therapies for preterm labor. ObsEva was founded in November 2012, by Ernest Loumaye MD, PhD and André Chollet PhD. Ernest Loumaye is a specialist in female reproductive medicine with 20 years of experience in the biopharmaceutical industry. Ernest Loumaye was previously Co-Founder and CEO of PregLem SA, a successful biopharmaceutical company which was acquired by Gedeon Richter in 2010. André Chollet is specialist in medicinal and pharmaceutical chemistry with more than 30 years of experience in diverse positions in the biopharmaceutical industry, including in Biogen, GSK and Merck Serono. André Chollet was responsible for the preterm labor program at Serono before the acquisition of the company by Merck KGaA.

Altamira Therapeutics is focused on developing innovative pharmaceutical therapies aimed at addressing unmet medical needs, particularly in neurotologic disorders affecting the inner ear. The company is recognized as a pioneer in creating treatments for hearing protection, tinnitus relief, and balance restoration. Among its product offerings is Bentrio, a drug-free nasal spray designed to provide personal protection against airborne viruses and allergens. Additionally, Altamira utilizes its OligoPhore/SemaPhore platform, which enables the complexation of therapeutic RNAs with proprietary peptides to create nanoparticle formulations. This technology facilitates the systemic delivery of therapeutic RNA to tissues impacted by leaky vasculature, which is characteristic of solid tumors and certain inflammatory conditions.

Marinus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics for rare seizure disorders and neuropsychiatric conditions. The company's primary product candidate, ganaxolone, is an allosteric modulator of GABAA receptors, designed for both intravenous and oral administration for various patient populations. It aims to address multiple indications, including status epilepticus, cyclin dependent kinase-like 5 deficiency disorder, PCDH19-related epilepsy, tuberous sclerosis complex, postpartum depression, and treatment-resistant depression. Marinus Pharmaceuticals collaborates with NovaMedica and has license agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals to advance its research and therapeutic offerings. Founded in 2003, the company is headquartered in Radnor, Pennsylvania.

Sophiris Bio is a biotech company that develops a treatment for the symptoms of benign prostatic hyperplasia. Their product includes topsalysin for the treatment of lower urinary tract symptoms of benign prostatic hyperplasia and for the treatment of low- to intermediate-risk prostate cancer.

IVERIC bio is a biopharmaceutical company dedicated to discovering and developing innovative treatment options for retinal diseases that have significant unmet medical needs. The company is actively working on therapeutic product candidates aimed at age-related retinal diseases, as well as gene therapy product candidates designed for orphan inherited retinal diseases. Through its focused research and development efforts, IVERIC bio seeks to address critical gaps in the treatment landscape for patients suffering from these conditions.

Labrys Biologics Inc. is a biotechnology company dedicated to developing treatments for chronic migraine. The company has secured worldwide rights to RN-307, an antibody initially developed by Pfizer Inc., specifically designed for the treatment of chronic migraine. Additionally, Labrys Biologics is advancing its lead candidate, LBR-101, which is an anti-CGRP monoclonal antibody aimed at preventing chronic and high-frequency migraines. Through these innovative therapies, Labrys Biologics aims to address the significant unmet medical needs of individuals suffering from chronic migraine conditions.

Salveo Specialty Pharmacy is an independent pharmacy that specializes in providing medications and clinical services to patients with chronic conditions. With a commitment to enhancing the wellness and health of its patients, Salveo works closely with customers, referral sources, and insurance plans to ensure effective communication and superior patient care. The company combines its expertise in specialty pharmacy, home infusion, and home healthcare to deliver comprehensive clinical support tailored to the needs of individuals managing long-term health issues.

Aclaris Therapeutics started by the founders of Vicept Therapeutics, is a privately held specialty pharmaceutical dermatology company focused on the development of novel dermatologic therapies. It is committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in dermatology, both medical and aesthetic, and immunology. Aclaris is focused on market segments with no FDA-approved medications or where treatment gaps exist.

Mirna Therapeutics, Inc. (Mirna) is a discovery-stage biopharmaceutical research and development company focused on miRNA-directed human oncology therapies. Featuring world-class research capabilities, a strong understanding of miRNA and cancer biology, and an expansive IP portfolio, Mirna Therapeutics is well-positioned to capitalize on the emerging field of miRNA-based therapeutics.

Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for hemophilia and other rare bleeding disorders. The company specializes in subcutaneous (SQ) coagulation factors designed to enhance blood clotting and improve patient outcomes compared to traditional intravenous (IV) therapies. Its product portfolio includes Marzeptacog alfa (activated), an engineered Factor VIIa that has completed Phase II development for hemophilia A or B patients with inhibitors, and Dalcinonacog alfa, a next-generation Factor IX therapy that has undergone Phase IIb clinical trials for hemophilia B. Additionally, Catalyst is developing CB 2679d-GT, a Factor IX gene therapy for hemophilia B, and CB 2782-PEG, a long-acting anti-C3 protease for dry age-related macular degeneration (AMD). The company has strategic collaborations with Mosaic Biosciences, Inc. for anti-complement factor 3 products and with Biogen International GmbH for the commercialization of pegylated CB 2782 targeting geographic atrophy associated with dry AMD. Established in 2002, Catalyst Biosciences is headquartered in South San Francisco, California.

Alimera Sciences is a pharmaceutical company focused on the research, development, and commercialization of prescription ophthalmic pharmaceuticals, particularly for diseases affecting the retina. The company’s primary product, ILUVIEN, is an intravitreal implant designed to treat diabetic macular edema (DME), a condition that poses a significant risk of vision loss in diabetic patients. ILUVIEN provides sustained release of the corticosteroid fluocinolone acetonide through a non-surgical procedure, allowing for a self-sealing wound. In addition to DME, the company also targets non-infectious uveitis affecting the posterior segment of the eye. Alimera operates in various international markets, including the United States, Germany, the United Kingdom, China, and the Middle East, utilizing both direct sales and distribution channels to reach physician offices, pharmacies, and hospitals. Founded in 2003 and headquartered in Alpharetta, Georgia, Alimera Sciences is dedicated to improving retinal health and vision preservation through innovative treatments.

SARcode Bioscience is a private biopharmaceutical company based in San Francisco that focuses on developing a novel class of small molecule antagonists targeting lymphocyte function-associated antigen-1 (LFA-1). These antagonists are being developed as topical agents aimed at addressing significant unmet medical needs in the fields of ophthalmology, dermatology, and other inflammatory diseases. By targeting LFA-1, SARcode aims to create innovative treatments that can improve patient outcomes in these areas.

Avantium is a leading technology company specialized in advanced high-throughput R&D for applications in the energy, chemicals and pharmaceutical industries. The company's headquarters and laboratories are located in Amsterdam, in the Netherlands. Avantium's proprietary high-throughput technology enables a faster and more cost-effective development of new and improved products and production processes. Using its unique rational approach towards the design of experiments and data analysis, Avantium is capable of accomplishing innovations with superior success rate. Avantium has demonstrated the validity and commercial viability of its technology by successfully providing research services and tools to more than 70 companies worldwide, including many industry leaders. The company's mission is to increase the success rate and economics of product and process development. Building on its expertise and track record in the energy, chemicals and pharmaceutical industries, Avantium focuses on developing products in two fields: new biofuels and bio-based chemicals, and new crystal forms of marketed drugs under patent. Avantium's strategy is to progress its development programs and exploit the commercial value of its expanding patent portfolio by securing value-adding partnerships during the coming years. Avantium seeks continuous expansion of its profitable services and tools business. Avantium has assembled a team of highly educated professionals who are experts in catalysis, crystallography, organic chemistry, engineering of robotic systems, process engineering, statistics, cheminformatics and software development. Its teams collaborate closely with partner R&D organizations.

Aerie Pharmaceuticals is an ophthalmic pharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for various eye diseases, including glaucoma, dry eye, and retinal conditions. The company's key products include Rhopressa, a once-daily eye drop designed to lower elevated intraocular pressure in patients with glaucoma or ocular hypertension, and Rocklatan, a fixed-dose combination of Rhopressa and latanoprost, also aimed at reducing intraocular pressure in open-angle glaucoma patients. Additionally, Aerie is developing AVX-012, a clinical-stage candidate for dry eye, alongside AR-1105 and AR-13503, which are sustained-release implants targeting retinal diseases. Founded in 2005, Aerie Pharmaceuticals is headquartered in Durham, North Carolina, and has a collaborative research agreement with DSM, reflecting its commitment to advancing eye care solutions.

NextWave Pharmaceuticals, a Cupertino, CA-based pharmaceutical company that develops and commercializes products utilizing proprietary drug delivery technology.

Vicept Therapeutics, Inc., located in Malvern, Pennsylvania, is a privately held specialty biopharmaceutical company founded in August 2009. The company focuses on developing innovative topically applied therapies aimed at treating erythema, or skin redness, associated with rosacea and other dermatological conditions characterized by redness and flushing. In addition to its research and development efforts, Vicept also manufactures and distributes dermatological therapeutic products, positioning itself as a key player in addressing unmet medical needs in skin health.

Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms. The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments that retain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies.

Aerie Pharmaceuticals is an ophthalmic pharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for various eye diseases, including glaucoma, dry eye, and retinal conditions. The company's key products include Rhopressa, a once-daily eye drop designed to lower elevated intraocular pressure in patients with glaucoma or ocular hypertension, and Rocklatan, a fixed-dose combination of Rhopressa and latanoprost, also aimed at reducing intraocular pressure in open-angle glaucoma patients. Additionally, Aerie is developing AVX-012, a clinical-stage candidate for dry eye, alongside AR-1105 and AR-13503, which are sustained-release implants targeting retinal diseases. Founded in 2005, Aerie Pharmaceuticals is headquartered in Durham, North Carolina, and has a collaborative research agreement with DSM, reflecting its commitment to advancing eye care solutions.

Alvine Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing therapeutics for autoimmune and gastrointestinal diseases, with a particular emphasis on celiac disease. The company's lead product candidate, ALV003, is an orally administered mixture of two gluten-specific proteases designed to degrade gluten, the primary immunologic trigger for celiac disease. In addition to ALV003, Alvine is working on proteases that target other aspects of celiac disease, including Transglutaminase 2 (TG2) and the HLA-DQ2 antigen. Founded in 2005 and based in San Carlos, California, Alvine Pharmaceuticals operates as a subsidiary of ImmunogenX, LLC as of February 2016.

Intellikine is engaged in the discovery and development of small molecule therapies that specifically target the PI3K/Akt/mTOR signaling pathway. The company focuses on creating innovative drug candidates aimed at treating various conditions, including cancer, inflammation, and autoimmune disorders. Its product lineup features INK128, an orally available TORC1/2 inhibitor designed for solid tumor malignancies, and INK1197, a dual PI3K selective inhibitor intended for patients suffering from immune-mediated inflammatory diseases like rheumatoid arthritis and asthma. Intellikine is dedicated to assembling a talented team and an effective discovery platform to accelerate the development of next-generation medical breakthroughs in kinase inhibitor therapies.

Hyperion Therapeutics is a biopharmaceutical company based in Brisbane, California, specializing in the development and commercialization of treatments for orphan diseases. The company focuses on therapeutics for urea cycle disorders (UCD) and hepatic encephalopathy, offering products such as RAVICTI, a nitrogen-binding agent for managing UCD in both adults and children, as well as BUPHENYL and AMMONAPS for specific UCD subtypes. In addition to its existing therapies, Hyperion is developing glycerol phenylbutyrate, an active component of RAVICTI, aimed at treating hepatic encephalopathy. Founded in 2006, Hyperion Therapeutics operates as a subsidiary of Horizon Pharma USA and is committed to addressing the needs of underserved patient populations in the United States and internationally.

Marinus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics for rare seizure disorders and neuropsychiatric conditions. The company's primary product candidate, ganaxolone, is an allosteric modulator of GABAA receptors, designed for both intravenous and oral administration for various patient populations. It aims to address multiple indications, including status epilepticus, cyclin dependent kinase-like 5 deficiency disorder, PCDH19-related epilepsy, tuberous sclerosis complex, postpartum depression, and treatment-resistant depression. Marinus Pharmaceuticals collaborates with NovaMedica and has license agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals to advance its research and therapeutic offerings. Founded in 2003, the company is headquartered in Radnor, Pennsylvania.

Vicept Therapeutics, Inc., located in Malvern, Pennsylvania, is a privately held specialty biopharmaceutical company founded in August 2009. The company focuses on developing innovative topically applied therapies aimed at treating erythema, or skin redness, associated with rosacea and other dermatological conditions characterized by redness and flushing. In addition to its research and development efforts, Vicept also manufactures and distributes dermatological therapeutic products, positioning itself as a key player in addressing unmet medical needs in skin health.

Aclaris Therapeutics started by the founders of Vicept Therapeutics, is a privately held specialty pharmaceutical dermatology company focused on the development of novel dermatologic therapies. It is committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in dermatology, both medical and aesthetic, and immunology. Aclaris is focused on market segments with no FDA-approved medications or where treatment gaps exist.

Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Malvern, Pennsylvania, dedicated to developing innovative therapies that aim to enhance the effectiveness of radiotherapy in cancer treatment. The company’s lead product candidate, avasopasem manganese (GC4419), is a small molecule dismutase mimetic currently undergoing Phase III clinical trials for the treatment of severe oral mucositis induced by radiation in patients with head and neck cancer. Additionally, it is being tested in Phase IIa trials for radiotherapy-induced esophagitis in lung cancer patients. Galera is also advancing a second candidate, GC4711, which is in Phase I/II trials targeting pancreatic and lung cancers. The company was founded in 2012 and is committed to addressing severe side effects associated with cancer treatments to improve patient outcomes.

Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for hemophilia and other rare bleeding disorders. The company specializes in subcutaneous (SQ) coagulation factors designed to enhance blood clotting and improve patient outcomes compared to traditional intravenous (IV) therapies. Its product portfolio includes Marzeptacog alfa (activated), an engineered Factor VIIa that has completed Phase II development for hemophilia A or B patients with inhibitors, and Dalcinonacog alfa, a next-generation Factor IX therapy that has undergone Phase IIb clinical trials for hemophilia B. Additionally, Catalyst is developing CB 2679d-GT, a Factor IX gene therapy for hemophilia B, and CB 2782-PEG, a long-acting anti-C3 protease for dry age-related macular degeneration (AMD). The company has strategic collaborations with Mosaic Biosciences, Inc. for anti-complement factor 3 products and with Biogen International GmbH for the commercialization of pegylated CB 2782 targeting geographic atrophy associated with dry AMD. Established in 2002, Catalyst Biosciences is headquartered in South San Francisco, California.

KaloBios Pharmaceuticals provides medicines for respiratory diseases and certain cancers. The company is a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases. They designed to overcome marketed antibody products.